EDIT-B is a first-in-class, clinically validated, CE marked blood test with excellent sensitivity and specificity for the differential diagnosis of bipolar disorder and depression.
The objective is to drastically reduce the diagnostic delay for bipolar disorder, which is today over seven years, and by doing so, to contribute to an optimized patients’ management for a better quality of life. EDIT-B aims to answer a major diagnostic unmet need with its unique technology based on the study of RNA and Artificial Intelligence.
EDIT-B is intended for adult patients treated for depression symptoms, as a decision-making support tool for mental healthcare providers.